FDA Intensifies Nationwide Inspections to Combat Counterfeit Health Products
The Food and Drug Administration (FDA) has made a firm commitment to ramp up its inspection activities across the country. In a statement released on Sunday, February 22, 2026, FDA Director General Paolo Teston emphasized the agency's dedication to ensuring that all establishments adhere to existing rules and regulations.
Comprehensive Inspection Focus Areas
Teston outlined that the inspections will cover multiple critical aspects of health product management. These include proper storage conditions, cold chain management for temperature-sensitive items, product registration status, licensing compliance, and thorough documentation requirements. The FDA will conduct both coordinated and unannounced inspections to maintain the integrity of the health product supply chain.
The primary goal is to protect consumers from unsafe and non-compliant products, Teston stated. He added that these efforts reinforce the FDA's commitment to safeguarding public health through sustained oversight, monitoring, and enforcement at all distribution levels.
Strict Enforcement Against Violators
The FDA chief made it clear that the agency will not hesitate to take action against health products and business establishments found in violation of regulations. Compliance is mandatory for all establishments, regardless of their size or location, Teston asserted.
Establishments caught breaking FDA laws and regulations will face immediate regulatory measures, including:
- Seizure of non-compliant products
- Suspension or revocation of licenses
- Closure of warehouses
- Filing of administrative and legal cases
Response to Senate Criticism
This nationwide inspection initiative follows recent criticism from senators who accused the FDA of lacking concrete action against the sale of illegal, counterfeit, and unregistered health products. Lawmakers urged the agency to move beyond merely issuing health advisories and take more decisive steps against non-compliant products.
The FDA's renewed vigilance aims to address these concerns directly, ensuring that regulatory actions are both proactive and effective in maintaining public safety.
